ZTS Stock Analysis: Buy, Sell, or Hold?
ZTS - ZOETIS INC.
$78.06
1.22 (1.58%)
▲
5d:
-1.61%
30d:
-4.02%
90d:
-32.67%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 8.9/10
Get Alerted When ZTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ZTS trading at deep discount. Market pricing in -12.8% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ZTS trading at deep discount. Market pricing in -12.8% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$153.84
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$95.52
18.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZTS is currently trading at $78.06, which is considered slightly low relative to its 30-day fair value range of $77.37 to $80.55. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.3) compared to its historical average (15.6). Remarkably, the market is currently pricing in an annual earnings decline of 12.8% over the next few years. This pessimistic expectation contrasts with the company's recent 6.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ZTS is in a strong downtrend. Immediate support is located at $75.64, while resistance sits at $82.98.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $124.59 (+62.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZTS is in a strong downtrend. Immediate support is located at $75.64, while resistance sits at $82.98.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $124.59 (+62.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$77.37 -
$80.55
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.1% below Wall St target ($124.59)
Trading Range Analysis
30-Day Trading Range
$77.37 -
$80.55
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$75.64
Resistance Level
$82.98
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.35
Wall Street Target
$124.59
(+62.1%)
Revenue Growth (YoY)
2.9%
Earnings Growth (YoY)
6.0%
Profit Margin
28.0%
Valuation Discount vs History
-12.8% cheaper
PE vs Historical
10.4 vs 15.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.8%
(market-implied from PE analysis)
1-Year Target
$69.16
(-10%)
2-Year Target
$62.24
(-19%)
3-Year Target
$56.02
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→16)
$84.43
(+10%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.7%)
$201.78
(+163%)
Base:
(SPY PE: 10.3, Growth: 7.7%)
$95.88
(+25%)
Bear:
(PE: 8.8, Growth: 7.7%)
$81.50
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 12.44 | Current EPS (TTM): $6.10
Bull Case
$101.60
(+32%)
Analyst growth 21.7%, PE expands to 13.7
Base Case
$92.37
(+20%)
Market implied 21.7%, PE stable at 12.4
Bear Case
$51.61
(-33%)
Severe decline -20.0%, PE contracts to 10.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.3 to 15.6
Stabilization Target:
$115.82
(+50.7%)
PE Expansion Potential:
+50.7%
Share & Embed Analysis
Last updated: June 24, 2026 2:28 PM ET
Data refreshes hourly during market hours. Next update: 3:28 PM
Data refreshes hourly during market hours. Next update: 3:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZTS showing a specific setup today?
Insider Activity (6 Months)
3
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 63 BUY |
Advanced ZTS Option Strategies
Professional options setups generated by AI based on today's ZTS price and gamma walls.
